Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Cash & Equivalents (2015 - 2026)

Argenx Se's (ARGX) quarterly Cash & Equivalents came in at $3.6 billion in Q2 2026, up 71.81% on a YoY basis from $2.1 billion in Q2 2025, and up 2.66% quarter-over-quarter from $3.5 billion in Q4 2025.

Analysis

Argenx Se (ARGX) Cash & Equivalents (2015 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Cash & Equivalents for 12 consecutive years, with $3.6 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash & Equivalents rose 71.81% year-over-year to $3.6 billion; the trailing twelve-month figure through Jun 2026 stood at $3.6 billion (up 71.81% YoY), and the FY2025 full-year result was $3.5 billion, up 132.73% from the prior year.
  • Cash & Equivalents grew to $3.6 billion in Q2 2026 per ARGX's latest filing, from $3.5 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $3.6 billion in Q2 2026 and bottomed at $800.7 million in Q4 2022.
  • Historically, Cash & Equivalents has averaged $1.9 billion across 5 years, with a median of $1.5 billion in 2024.
  • The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 40.0% in 2022, then surged 155.87% in 2023.
  • Over 5 years, Cash & Equivalents stood at $800.7 million in 2022, then soared by 155.87% to $2.0 billion in 2023, then fell by 26.79% to $1.5 billion in 2024, then surged by 132.73% to $3.5 billion in 2025, then grew by 2.66% to $3.6 billion in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods registered $3.6 billion, $3.5 billion, and $2.1 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 13.99 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 3.18 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 6.14 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 2.46 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 3.58 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 1.72 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 1.71 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 1.29 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 544.80 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn 11.32 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.58 Bn
Dec 31, 2025 3.49 Bn
Jun 30, 2025 2.09 Bn
Dec 31, 2024 1.50 Bn
Jun 30, 2024 1.44 Bn
Dec 31, 2023 2.05 Bn
Jun 30, 2023 1.11 Bn
Dec 31, 2022 800.74 Mn
Jun 30, 2022 1.37 Bn
Dec 31, 2021 1.33 Bn
Jun 30, 2021 1.58 Bn
Dec 31, 2020 1.18 Bn
Jun 30, 2020 1.35 Bn
Dec 31, 2019 366.69 Mn
Jun 30, 2019 188.54 Mn
Dec 31, 2018 320.78 Mn
Jun 30, 2018 168.12 Mn
Dec 31, 2017 224.73 Mn
Jun 30, 2017 83.05 Mn
Dec 31, 2016 97.06 Mn